China’s streamlined clinical trial system for investigator-initiated trials is facing scrutiny after the deaths of three participants in investigator-initiated trials (IITs). The reporting centers on the IIT model, where experimental cell and other interventions can be tested with faster setup than traditional sponsored pathways. The concerns come as China’s regulatory approach for early trial access has been widely discussed for speed, cost, and administrative quietness. The deaths have triggered renewed debate about participant protection and oversight in IIT settings. While the details of causality are not established in the coverage, the episode is likely to influence how sponsors and academic investigators handle reporting requirements, monitoring intensity, and trial governance. For biopharma companies partnering with Chinese academic sites, the developments could affect diligence expectations and contractual terms around safety oversight and data transparency.